On May 26, 2020 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, reported that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Scientific Program held May 29-31, 2020 (Press release, Nucleix, MAY 26, 2020, View Source [SID1234558498]). The six-marker assay serves as an initial component of Nucleix’s screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Monitoring methylation changes in tumors that shed circulating cell-free DNA demonstrates an alternative approach to identifying many cancers, particularly at early stages, with just a handful of markers that are measured using the power of our proprietary EpiCheck technology," said Chris Hibberd, chief executive officer of Nucleix. "We have already seen success with this platform, having discovered, developed and launched a bladder cancer recurrence test kit in Europe and advanced a new test for patients at high-risk for lung cancer based on encouraging results seen with a disease specific panel. We look forward to sharing updates on the promising data supporting our Lung EpiCheck for patients at high risk for lung cancer."
Details are as follows:
Title: Discovery of a core-panel of markers for a blood-assay for cancer detection utilizing cfDNA methylation changes (#1522)
Presenter: Dr. Lasika Seneviratne, SCORA/LA Cancer Network